Preparation for chemical composition of Shenmai injection and application in treating cardiovascular and cerebrovascular diseases thereof

A technology of Shenmai injection and Ophiopogon japonicus, applied in the preparation of chemical components of Shenmai injection and its application in the treatment of cardiovascular and cerebrovascular diseases, can solve the lack of effective quality control methods for Ophiopogon japonicus, Shenmai injection Unfavorable liquid quality control, unfavorable quality control of Ophiopogon japonicus, etc., to achieve stable and reliable product quality, complete product quality standards, and improved product quality

Active Publication Date: 2008-05-07
CHIATAI QINGCHUNBAO PHARMA
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Shenmai needles have been clinically used for more than 20 years, but the active ingredients in them have not been very clear. The current quality standards for Shenmai needles only stipulate three ginsenosides Rb in ginseng (red ginseng) 1 , Rg 1 and Re content determination, but did not reflect the active ingredients of another medicinal material Radix Radix in the prescription at all, which is very unfavorable to the quality control of Radix Radix in the pr...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation for chemical composition of Shenmai injection and application in treating cardiovascular and cerebrovascular diseases thereof
  • Preparation for chemical composition of Shenmai injection and application in treating cardiovascular and cerebrovascular diseases thereof
  • Preparation for chemical composition of Shenmai injection and application in treating cardiovascular and cerebrovascular diseases thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] 1. Preparation method of compound I-VIII

[0024] (1) Reagents and separation materials:

[0025] The solvents used for separation (ethanol, petroleum ether, chloroform, acetone, methanol, ethyl acetate) are analytically pure solvents. The solvent used in the preparative high performance liquid phase is acetonitrile which is chromatographically pure. The water is self-made twice-redistilled water, and the other separation water is Distilled water.

[0026] 200-300 mesh column chromatography silica gel and thin layer chromatography silica gel H, Qingdao Ocean Chemical Group Co., Ltd.

[0027] High-efficiency thin-layer silica gel plate: HSGF254, Zhifu Huangwu Silicone Development and Testing Plant, Yantai City, Shandong Province, Yantai

[0028] ODS Reversed Phase Silica Gel (RP-18): Green Baicao Technology Development Co., Ltd., Beijing

[0029] Macroporous resin: D-1400 type macroporous resin, Yangzhou Pharmaceutical Factory, Yangzhou

[0030] Sephadex: Sephadex LH-20, Pha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Login to view more

Abstract

The invention discloses three compounds of hydroxide radical methyl ophiopogonanone B (hereinafter referred as 6), 2Belta-hydroxide radical methyl ophiopogonanone A (hereinafter referred as 7a) and 2Alpha- hydroxide radical methyl ophiopogonanone A (hereinafter referred as 7b) for SMI and the preparation method thereof. The invention also discloses a method for controlling the quality of the SMI so as to control the compound 6, 7a and 7b and active compound methyl ophiopogonanone B (hereinafter referred as 5), ophiopogonin A (hereinafter referred as 8) and ginsenoside Rb1 with a fixed quantity. A plurality of researches prove that the components can be the main active substances of caring cardiovascular disease through the SMI. As the invention is added with ophiopogon angiocarpy active ingredient as a quality control standard, the quality of the SMI product is more stable and reliable when compared with the traditional quality control art, thereby fundamentally solving the problem of being unbeneficial for the quality control of the ophiopogon part during the traditional SMI production process.

Description

Technical field [0001] The invention relates to a preparation method of a new compound and active chemical composition of a traditional Chinese medicine injection for the treatment of cardiovascular and cerebrovascular diseases, and its application in the treatment of cardiovascular diseases and in quality control. Background technique [0002] Shenmai Injection (also known as "Shenmai Injection", hereinafter referred to as "Shenmai Needle") is a derivative of the ancient prescription "Shengmai San", which is extracted and processed from two traditional Chinese medicinal materials, red ginseng and Ophiopogon japonicus. It is used to treat shock, coronary heart disease, viral myocarditis, chronic pulmonary heart disease, and neutropenia of deficiency of both qi and yin. It is a national protection product of traditional Chinese medicine and is a basic emergency medicine. Shenmai Needle has been clinically used for more than 20 years, but the active ingredients in it have not been ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D311/22C07D407/06A61K31/352A61P9/00
Inventor 朱大元黎豫杭许正宇箫耀龙李云森谭昌恒蒋福祥柯嘉敏文英强张善飞柴建国
Owner CHIATAI QINGCHUNBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products